A Phase 4 interventional study of Atenolol Pill and Propranolol Pill in Spinal Tumor, Spinal Hemangioma and Beta Blocker Toxicity, sponsored by Center for Vascular Pathology, Moscow. Status unknown at 1 site in Russian Federation. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-11-03.
Sponsored by Center for Vascular Pathology, Moscow · Phase 4, Interventional, and Treatment
Spinal hemangioma is one of the most common benign vertebral tumours. Being mostly asymptomatic, it is still associated with a pain syndrome especially if encroaches into the neural canal.
This study is organised to evaluate the efficacy and safety of β-blockers drugs in adults with spinal hemangioma.
105 studies on the registry are indexed under Spinal Cord Neoplasms; 27 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 50 across 69 interventional studies indexed under Spinal Cord Neoplasms.
Browse Spinal Cord Neoplasms studies →Center for Vascular Pathology, Moscow is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately
Drug: Atenolol Pill
The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately
Drug: Propranolol Pill
Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.
Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.
Reducing tumor growth
MRI
Time frame: 3 months
Reducing tumor
MRI
Time frame: 6 months
Life-quality
Valid questionnaires based on the ones, approved by EuroQol Organization
Time frame: 3 months and 6 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2021; primary completion for Dec 2022, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Center for Vascular Pathology, Moscow